Scientists find anti-malarial drug may be repurposed to treat Zika

 New Delhi: (India Science Wire): In their search for possible treatment forZika virus infection, a team of Indian researchers has identified aviral protein that can be targeted by an already available antimalarial drug,hydroxychloroquine (HCQ).

Researchers hit upon the protein when they conducted a high throughput virtual screening of a library of drugsapproved by America’s Food and Drugs Authority. 

Out of 1861 compounds in the library, five including HCQappeared to be possible candidates for treatment of Zika virus. It has also been found that HCQ limits the Zika virus transmissionfrom mother to foetus.

The study was conducted by researchers at the Indian Institute of Technology, Mandi, Alagappa University in Karaikudi, Tamil Nadu and Washington University at St. Louis. 
 “Hopefully we are close to finding a potential drug against Zika. 
 
 We have successfully identified the target protein on which HCQ acts. Since it is an FDA approved drug our journey for validation may be less tedious and we can go for preclinical trials faster,” said Dr Rajanish Giri, researcher at IITMandi, while speaking with India Science Wire. 
 
“Repurposing approved drugs can be an efficient method to identify drug compounds, which may be capable of activating or inhibiting new targets. This approach has some advantageous features, including reduced development time and expense and improved safety” he added. 

Zikagets transmitted by bite of an infected mosquito from the Aedes genus, mainly Aedesaegypti. This is the same mosquito that transmits dengue, chikungunya and yellow fever. This virus infection during pregnancy is a cause of microcephaly (reduced head size)and other congenital abnormalities in developing foetus and newborns. 

Zika infection in pregnancy also results in pregnancy like foetal loss, stillbirth and preterm birth. Further, it isknown tobe associated with certain neurological disorders like Guillain-Barré syndrome in adults and cause problems like neuropathy and myelitis particularly in older children and adults.

The rapid spread of this virus in recent yearshas led to a surge in efforts to find an effective therapeutic intervention. A paper on the work has been recently been published in journal ACS Omega